VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CLColgate-Palmolive Company
$92.40$73.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCLFinancials

Colgate-Palmolive Company (CL) Financials

30Y historyFree accessUpdated daily

Revenue growth recovered to 8.4% in 2026Q1, though operating margins have compressed from 23.2% in 2024Q1 to 21.7% due to scaling SG&A expenses.

CL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue20.8B20.38B20.1B19.46B17.97B17.42B16.47B15.69B15.54B15.45B15.2B16.03B17.28B17.42B17.09B16.73B15.56B15.33B15.33B13.79B12.24B11.4B10.58B9.9B9.29B9.43B9.36B9.12B8.97B9.06B8.75B
Revenue Growth %4.26%1.4%3.31%8.29%3.13%5.77%4.96%0.96%0.58%1.7%-5.23%-7.19%-0.82%1.96%2.1%7.52%1.55%-0.02%11.17%12.68%7.38%7.68%6.87%6.55%-1.42%0.75%2.63%1.63%-0.94%3.52%4.68%
Cost of Goods Sold8.3B8.13B8B8.21B7.82B7.13B6.54B6.42B6.34B6.13B6.06B6.66B7.17B7.2B7.17B7.12B6.39B6.3B6.66B5.92B5.36B5.11B4.76B4.46B4.22B4.24B4.27B3.88B3.96B4.14B4.13B
COGS % of Revenue-39.89%39.77%42.18%43.51%40.92%39.69%40.88%40.77%39.67%39.9%41.56%41.51%41.35%41.96%42.54%41.03%41.12%43.47%42.95%43.77%44.81%44.95%45%45.45%44.94%45.58%42.59%44.14%45.73%47.26%
Gross Profit12.49B12.25B12.11B11.25B10.15B10.29B9.93B9.28B9.21B9.32B9.13B9.37B10.11B10.22B9.92B9.62B9.18B9.02B8.67B7.87B6.88B6.29B5.83B5.45B5.07B5.19B5.09B5.23B5.01B4.92B4.61B
Gross Margin %60.06%60.11%60.23%57.82%56.49%59.08%60.31%59.12%59.23%60.33%60.1%58.44%58.49%58.65%58.04%57.46%58.97%58.88%56.53%57.05%56.23%55.19%55.05%55%54.55%55.06%54.42%57.41%55.86%54.27%52.74%
Gross Profit Growth %-1.2%7.6%10.85%-1.39%3.62%7.07%0.77%-1.26%2.09%-2.54%-7.27%-1.1%3.04%3.13%4.76%1.71%4.13%10.15%14.33%9.41%7.96%6.95%7.44%-2.33%1.93%-2.71%4.45%1.96%6.52%7.17%
Operating Expenses8.09B7.9B7.72B7.12B6.57B6.41B6.02B5.51B5.36B5.31B5.17B5.4B5.92B6.09B5.91B5.75B5.41B5.28B5.34B4.93B4.31B3.92B3.62B3.22B3.06B3.33B3.37B3.59B3.53B3.56B3.37B
OpEx % of Revenue-38.77%38.42%36.59%36.54%36.78%36.56%35.14%34.46%34.39%34.04%33.68%34.27%34.94%34.59%34.35%34.79%34.46%34.84%35.75%35.21%34.39%34.25%32.53%32.89%35.32%36.03%39.42%39.32%39.27%38.5%
Selling, General & Admin8.12B7.9B7.81B6.78B6.25B6.1B5.73B5.23B5.08B5.03B4.88B5.13B5.64B5.82B5.65B5.49B5.16B5.01B5.09B4.68B4.07B3.67B3.4B3.3B3.03B3.26B3.3B3.25B3.2B3.24B3.05B
SG&A % of Revenue-38.77%38.85%34.83%34.76%35.02%34.8%33.35%32.67%32.54%32.14%31.97%32.66%33.4%33.08%32.78%33.14%32.71%33.19%33.92%33.24%32.23%32.08%33.28%32.64%34.6%35.26%35.69%35.64%35.74%34.89%
Research & Development00355M343M320M307M290M281M277M285M289M274M277M267M259M262M256M269M253.1M247M241.5M246.3M229.2M00000000
R&D % of Revenue--1.77%1.76%1.78%1.76%1.76%1.79%1.78%1.84%1.9%1.71%1.6%1.53%1.52%1.57%1.64%1.76%1.65%1.79%1.97%2.16%2.17%--------
Other Operating Expenses1000K0-442M00000000000000006.2M000-74.3M23M68M72.1M340.2M330.3M319.9M316.3M
Operating Income4.41B4.35B4.38B4.13B3.58B3.89B3.91B3.76B3.85B4.01B3.96B3.97B4.18B4.13B4.01B3.87B3.76B3.74B3.33B2.94B2.57B2.37B2.2B2.17B2.01B1.86B1.72B1.64B1.48B1.36B1.25B
Operating Margin %21.21%21.33%21.8%21.23%19.95%22.31%23.74%23.97%24.77%25.94%26.06%24.76%24.22%23.71%23.45%23.11%24.18%24.41%21.69%21.3%21.02%20.8%20.8%21.87%21.66%19.74%18.39%17.98%16.54%15%14.24%
Operating Income Growth %--0.8%6.1%15.23%-7.75%-0.64%3.96%-2.29%-3.97%1.24%-0.25%-5.14%1.31%3.12%3.59%2.74%0.59%12.54%13.19%14.19%8.51%7.68%1.64%7.6%8.16%8.17%4.93%10.48%9.28%9.02%10.69%
EBITDA5.05B4.98B4.99B4.7B4.13B4.44B4.45B4.28B4.36B4.48B4.4B4.42B4.63B4.57B4.43B4.29B4.14B4.09B3.67B3.27B2.9B2.7B2.53B2.48B2.31B2.2B2.06B1.98B1.81B1.68B1.56B
EBITDA Margin %24.28%24.42%24.81%24.15%22.99%25.5%27.02%27.28%28.06%29.02%28.98%27.56%26.78%26.23%25.94%25.62%26.6%26.7%23.96%23.72%23.71%23.69%23.9%25.06%24.85%23.31%22%21.71%20.22%18.53%17.85%
EBITDA Growth %-0.06%-0.2%6.17%13.75%-7.02%-0.18%3.95%-1.83%-2.74%1.84%-0.36%-4.5%1.25%3.14%3.33%3.57%1.15%11.44%12.27%12.76%7.45%6.74%1.93%7.44%5.1%6.75%3.96%9.12%8.13%7.43%9.56%
D&A (Non-Cash Add-back)638M630M605M567M545M556M539M519M511M475M443M449M442M439M425M421M376M351M347.6M333.9M328.7M329.3M327.8M315.5M296.5M336.2M337.8M340.2M330.3M319.9M316.3M
EBIT3.25B3.33B4.25B3.68B2.83B3.2B3.81B3.49B3.66B3.64B3.89B2.9B3.66B3.68B3.95B3.85B3.5B3.63B3.11B2.73B2.23B2.28B2.17B2.23B2.01B1.83B1.74B1.64B1.48B1.36B1.25B
Net Interest Income-188M-192M-225M-232M-153M-100M-141M-145M-143M-102M-99M-26M-24M9M-15M-52M-59M-77M-95.6M-156.6M-158.7M-136M-119.7M00000000
Interest Income76M75M67M55M14M17M19M47M50M51M50M107M106M125M65M6M6M11M10M10M7.9M6.5M4M00000000
Interest Expense264M267M292M287M167M117M160M192M193M153M149M133M130M116M80M58M65M88M105.6M166.6M166.6M142.5M123.7M002.02B00000
Other Income/Expense-1.41B-1.29B-427M-739M-925M-799M-264M-461M-386M-522M-222M-1.21B-652M-566M-132M-78M-334M-204M-319.7M-373.9M-513.1M-236.3M-151.2M-124.1M-142.8M-166.1M-173.3M-245.2M-234.1M-255.9M-291.2M
Pretax Income3B3.06B3.96B3.39B2.66B3.09B3.65B3.3B3.46B3.49B3.74B2.76B3.53B3.56B3.87B3.79B3.43B3.54B3.01B2.56B2.06B2.13B2.05B2.04B1.87B1.67B1.57B1.39B1.25B1.1B954.6M
Pretax Margin %14.42%15.01%19.68%17.43%14.8%17.72%22.14%21.03%22.29%22.56%24.6%17.23%20.45%20.46%22.67%22.64%22.04%23.08%19.6%18.59%16.83%18.73%19.37%20.62%20.12%17.7%16.75%15.29%13.93%12.17%10.91%
Income Tax783M798M907M937M693M749M787M774M906M1.31B1.15B1.22B1.19B1.16B1.24B1.24B1.12B1.14B967.9M759.1M648.4M727.6M675.3M620.6M582M522.1M503.4M457.3M401.5M361.9M319.6M
Effective Tax Rate %26.12%26.09%22.93%27.62%26.05%24.26%21.58%23.45%26.15%37.65%30.82%43.97%33.8%32.4%32.09%32.59%32.57%32.25%32.21%29.61%31.49%34.09%32.94%30.39%31.12%31.29%32.12%32.79%32.12%32.83%33.48%
Net Income2.09B2.13B2.89B2.3B1.78B2.17B2.69B2.37B2.4B2.02B2.44B1.38B2.18B2.24B2.47B2.43B2.2B2.29B1.96B1.74B1.35B1.35B1.33B1.42B1.29B1.15B1.06B937.3M848.6M740.4M635M
Net Margin %10.04%10.46%14.37%11.82%9.93%12.43%16.36%15.08%15.44%13.1%16.06%8.63%12.62%12.86%14.47%14.53%14.15%14.95%12.77%12.6%11.06%11.86%12.54%14.35%13.86%12.16%11.37%10.28%9.46%8.18%7.26%
Net Income Growth %-27.96%-26.2%25.61%28.85%-17.59%-19.63%13.86%-1.38%18.58%-17.08%76.37%-36.51%-2.72%-9.34%1.69%10.35%-3.84%17.05%12.65%28.37%0.15%1.83%-6.63%10.32%12.36%7.78%13.5%10.45%14.61%16.6%269.19%
Net Income (Continuing)2.21B2.26B3.05B2.46B1.97B2.34B2.86B2.53B2.56B2.17B2.59B2.63B2.34B2.41B2.63B2.55B2.31B2.4B2.04B1.74B1.35B1.35B1.33B1.42B1.29B1.15B1.06B937.3M848.6M740.4M635M
Discontinued Operations0000000000000000000000000000000
Minority Interest341M311M332M348M405M362M358M441M299M303M260M255M240M231M201M166M142M141M0109.9M00261M00000000
EPS (Diluted)2.592.633.512.772.132.553.142.752.752.282.721.522.362.382.582.472.152.191.831.601.231.221.171.231.100.950.850.740.650.560.49
EPS Growth %-27.29%-25.07%26.71%30.05%-16.47%-18.79%14.18%0%20.61%-16.18%78.95%-35.59%-0.84%-7.75%4.45%14.88%-1.83%19.67%14.37%30.08%0.82%4.27%-4.88%11.82%15.79%11.76%14.86%13.85%16.07%14.29%276.92%
EPS (Basic)-2.643.532.782.132.563.152.762.762.302.741.532.382.412.602.492.232.271.911.681.291.271.231.301.171.010.910.790.700.610.53
Diluted Shares Outstanding805.1M811.1M822.5M829.2M838.8M848.3M859.3M861.1M873M887.8M898.4M909.7M924.3M939.9M960.2M984M1.02B1.05B1.07B1.07B1.08B1.09B1.12B1.13B1.16B1.19B1.23B1.25B1.27B1.27B1.25B
Basic Shares Outstanding802.3M808.7M817.7M827.4M836.4M845M856.8M859.1M870.6M881.8M891.8M902.2M915.1M930.8M952.2M976.6M975.6M999M1.01B1.02B1.03B1.04B1.06B1.07B1.09B1.11B1.15B1.17B1.18B1.18B1.17B
Dividend Payout Ratio-85.51%61.92%76.04%94.73%77.52%55.73%68.19%66.29%75.54%61.78%107.88%66.33%61.67%51.66%49.49%51.84%42.82%45.42%43.14%50.08%44.93%40.4%35.66%32.09%34.6%35.95%39.05%40.73%45.03%46.65%

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Emerging market currency volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Shows Mixed Momentum

According to the latest quarterly income statement, Colgate-Palmolive reported revenue growth of 8.4% in 2026Q1, a notable recovery from the 3.0% contraction observed in 2025Q1, suggesting that the company's underlying demand remains resilient despite significant geographic exposure to volatile emerging market economies.

The recent acceleration in top-line growth appears to be driven by a combination of pricing actions and volume recovery in the pet nutrition segment. Investors should monitor whether this growth is sustainable or if it remains susceptible to the translation headwinds that have historically masked operational progress in non-USD denominated markets.

Structural Gross Margin Resilience Persists

As reported in financial statements, Colgate-Palmolive maintained a robust gross margin of 60.6% in 2026Q1, consistently hovering near the 60% threshold over the last ten quarters, which underscores the company's significant pricing power and the premium nature of its therapeutic oral care and pet nutrition portfolios.

This margin profile suggests that the company successfully mitigates raw material inflation through its professional-recommendation flywheel. The ability to sustain these levels despite global supply chain pressures indicates a competitive moat that is structurally superior to traditional household product peers.

Operating Leverage Remains Under Pressure

Based on the provided income statement data, operating margins have experienced a slight compression from 23.2% in 2024Q1 to 21.7% in 2026Q1, indicating that SG&A expenses are currently scaling at a rate that slightly outpaces the growth in gross profit across the company's primary business segments.

This trend suggests that management is prioritizing market share retention and brand investment over immediate operating margin expansion. Analysts should investigate whether this increased overhead is a temporary strategic investment in pet nutrition capacity or a permanent shift in the company's cost structure.

Earnings Volatility Masks Operational Stability

As evidenced by the 2025Q4 net loss of $37 million followed by a rebound to $646 million in 2026Q1, reported net income appears highly sensitive to non-operating items and periodic accounting adjustments, which may obscure the underlying cash-generating capability of the core business operations.

The significant variance in quarterly net income warrants caution, as it does not necessarily reflect a deterioration in the company's fundamental business model. Investors should focus on normalized earnings metrics to better gauge the true profitability of the firm's global operations.

Margin Compression Risks Remain Elevated

While the company maintains strong margins, the recent trend of rising SG&A costs relative to revenue growth, as seen in the 2026Q1 figures, suggests that the company may be reaching a point of diminishing returns on its current marketing and distribution spend in competitive global markets.

Short-term investors should be wary of the potential for further margin erosion if the company is forced to increase promotional spending to defend its market share against private label entrants. The reliance on high-margin pet nutrition growth may also be vulnerable if consumer spending patterns shift toward lower-cost alternatives.

CL — Frequently Asked Questions

Quick answers to the most common questions about buying CL stock.

What was Colgate-Palmolive Company's (CL) revenue in 2025?

For fiscal year 2025, Colgate-Palmolive Company (CL) reported total revenue of $20.38B. This represents a 133.0% increase compared to $8.75B in 1996.

Is Colgate-Palmolive Company (CL) profitable?

Colgate-Palmolive Company (CL) is profitable, generating $2.13B in net income for the fiscal year ending 2025 with a net profit margin of 10.5%.

What is Colgate-Palmolive Company's operating profit margin?

Colgate-Palmolive Company (CL) reported an operating income of $4.35B, resulting in an operating profit margin of 21.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Colgate-Palmolive Company's gross profit and gross margin?

Colgate-Palmolive Company (CL) generated $12.25B in gross profit for the year, representing a gross profit margin of 60.1%. This demonstrates the company's core pricing power and production efficiency.